Hainan Boao Lecheng Medical Tourism (2026): China's Only Cross-Border Care Zone Opens One-Stop Hub

Boao Lecheng Medical Tourism: Complete Guide (2026)

What Makes Lecheng Different from Mainland China Hospitals

Lecheng is a Special Medical Zone — a small geographic area in Qionghai (on Hainan island) where China's national drug regulator allows drugs and devices already approved overseas to be used in clinical practice, often before those same products can be used elsewhere in the country. The mechanism is officially called "the only area in China with special rules for cross-border medical care, research, operations, and international exchange."

For international patients, that distinction matters. A drug approved in the US, EU, or Japan last year can be used in Lecheng now — without the multi-year wait for full NMPA approval in the rest of China. For patients with serious conditions who have already exhausted approved options at home, that gap can be the difference between getting treated and waiting.

The 570 approved drugs and devices cover oncology, rare diseases, ophthalmology, regenerative medicine, and medical aesthetics. The zone also has a separate channel for investigational therapies, including cell therapies and gene therapies, used under controlled conditions with informed consent.

What Treatments Are Available in Lecheng

The zone's clinical focus is narrow but deep. The most common referral reasons from international patients are:

• Boron neutron capture therapy (BNCT): A targeted radiation therapy for recurrent head and neck cancers, melanoma, and some brain tumors. The neutron source is at the Hainan BNCT Center (a separate facility from the hospital cluster but operationally linked). Treatment courses are short — typically one to two sessions — and the recovery window is faster than conventional external beam radiation.
• Cell and gene therapies: CAR-T and related engineered cell therapies, including some products not yet available in other Chinese hospitals. Pricing is typically 30–50% below US equivalents.
• Targeted oncology drugs and ADCs: Antibody-drug conjugates and next-generation targeted therapies approved in the US, EU, or Japan but not yet in the rest of China. The zone is the only legal channel for many of these.
• Regenerative medicine and stem cell therapies: Orthopedic and neurological applications, including for joint disease and post-stroke recovery. Hainan-based clinics have built a notable reputation in orthobiologics over the past five years.
• Premium ophthalmology and refractive surgery: The zone hosts the Hainan branch of several major ophthalmology centers, including international-standard cataract and refractive suites.
• Medical aesthetics and longevity programs: Licensed aesthetic procedures using devices and injectables that are approved abroad but pending full Chinese approval.

Who Is Using Lecheng Right Now

The 2025 patient mix skewed toward three groups:

• Russian patients — The largest single foreign cohort. Many come across the border via Hainan's visa-free policy for Russian travelers, which permits stays of up to 30 days. Cancer, orthopedics, and dental are the most common treatment categories.
• Middle Eastern patients — Mostly from the Gulf states, often coming for cancer and rare disease treatments not available in their home countries. The Russian cohort and Middle Eastern cohort together account for the majority of non-Chinese patient volume.
• Southeast Asian and Canadian patients — Smaller but growing cohorts. Cardiology, oncology, and reproductive medicine are common referral reasons.

How the New One-Stop Service Center Works

The center that opened in May 2026 bundles several practical services that previously had to be arranged separately:

• Visa assistance: Coordination with Chinese consulates abroad for medical visa invitation letters. Lecheng is included in Hainan's broader visa-free network, but patients needing longer stays (for complex treatment) still need formal medical visa documentation.
• Cross-border transfer coordination: Hospital-to-hospital handovers for patients coming from overseas institutions, including translation of medical records and synchronized appointments.
• Recovery care and cultural tourism: Post-treatment recovery packages that combine accommodation, light rehabilitation, and tourism in Qionghai and surrounding areas. The Russian patient who received BNCT in May spent several days in Qionghai after discharge — that pattern is now a designed offering rather than an ad hoc one.
• Foreign-language hotline and international visitor management platform: Multilingual support (English, Japanese, Thai, Arabic at the major facilities) and a centralized case management system across the 40+ institutions in the zone.
• Service officer system: Each foreign patient is assigned a dedicated staff member who follows them through the entire journey — from pre-arrival paperwork to post-treatment follow-up.

Hospitals and Facilities Inside the Zone

The zone has been built around a small number of high-investment specialty centers and a longer tail of partnership clinics:

• Boao Super Hospital — The flagship facility, a consortium of top-tier Chinese hospitals operating joint clinical centers. Includes specialty clinics in oncology, ophthalmology, and regenerative medicine.
• Hainan Mellsser Hospital — A joint venture with a Russian medical group, with multilingual staff covering English, Japanese, Thai, and Arabic. Partners include the Mayo Clinic and Cedars-Sinai for clinical collaboration and second opinions.
• Ruijin Hospital Hainan Branch — A branch of Shanghai's Ruijin Hospital, one of China's oldest and most respected tertiary institutions. Brings Shanghai-grade specialists to Hainan on rotation.
• Hainan BNCT Center — Home to one of the few clinical boron neutron capture therapy units in East Asia. Operated in partnership with a Chinese nuclear medicine institute.
• Ge Da (Gemei) Affiliated Plastic Surgery Hospital — Aesthetic and reconstructive surgery, including licensed international products.

The Treatment Process for International Patients

Coming to Lecheng from abroad typically follows this path:

• Pre-arrival (remote, 1–3 weeks): Submit medical records (translated to English or Chinese, MRI/CT scans on disc, pathology reports, and prior treatment history). The zone's medical review committee determines whether the requested treatment is available and appropriate.
• Visa and travel: Patients from 86 countries use Hainan's visa-free entry. Those needing longer stays apply for an S1 medical visa using the zone's invitation letter.
• Arrival and assessment (2–4 days): In-person consultation, imaging, and final treatment planning at the assigned facility.
• Treatment window: Varies by treatment. BNCT is typically 1–2 sessions. Cell therapy is a 3–6 week protocol. Aesthetic and ophthalmology procedures are often same-day or short-stay.
• Recovery and tourism (1–3 weeks): The zone arranges beachside recovery accommodation in Qionghai or Sanya. The Russian BNCT patient in May spent about a week touring Qionghai after discharge before flying home.
• Follow-up: Remote consultation via the international visitor management platform. Patients who need additional treatment cycles return under the same coordination framework.

Medical Tourism Comparison: Lecheng vs Singapore vs Thailand vs Japan (2026)

Data sources: China Daily (June 2026) on Lecheng services launch; Straits Times (June 2025) on Perennial Tianjin; Hainan provincial government data on visa-free entries; industry estimates for Singapore, Thailand, and Japan medical tourism.

Patient Decision Guide: Is Lecheng the Right Choice for You?

Who Should Consider Boao Lecheng

• Cancer patients who need a drug or device that has been approved abroad but is not yet available in the rest of mainland China — and who cannot wait for full NMPA approval
• Patients with recurrent head and neck cancers or melanoma who may benefit from boron neutron capture therapy as a precision radiation option
• Patients needing CAR-T or other cell therapies at lower cost than Singapore, Japan, or the US — at prices typically 50–70% below US levels
• Russian, Middle Eastern, or Southeast Asian patients for whom Hainan is closer and easier to reach than traditional medical tourism destinations
• Patients with rare disease indications whose treatment requires a drug only available abroad — the Lecheng track may be the only legal way to access it in mainland China
• Patients who want to combine treatment with a recovery holiday — Hainan's tropical climate and tourism infrastructure are designed for it

Who Should NOT Go to Lecheng

• Patients whose treatment is already fully available at a major public hospital in Beijing, Shanghai, or Guangzhou — Lecheng is for treatments that are not yet available elsewhere
• Patients who need emergency or trauma care — Lecheng is for elective specialty treatment, not acute care. In an emergency, the nearest comprehensive hospital on the mainland is the right destination.
• Patients with severe comorbidities that make elective travel risky — any medical tourism requires fitness to fly and a stable baseline condition
• Patients who cannot tolerate the visa-free or S1 visa process — Hainan does not yet have a dedicated medical tourism visa, and the 30-day visa-free window is too short for some long treatment protocols (this has been flagged by hospital chiefs as a barrier at the 2025 parliamentary session)
• Patients expecting a US- or Singapore-style hospital experience throughout — Lecheng facilities are high-quality and many are new, but service culture is still being developed and English fluency varies by department

What to Prepare Before Arrival

• Translated medical records: Full medical history, including imaging on disc, pathology slides, and treatment timelines. Lecheng's medical review committee works in Chinese, so translation is essential.
• Prior authorization for the specific treatment: Most cross-border drugs and devices in Lecheng require pre-screening. Submitting records early avoids a wasted trip.
• Visa documentation: Visa-free entry works for stays under 30 days for citizens of the 86 eligible countries. Longer stays need an S1 visa, which the zone can help arrange with an invitation letter.
• Funding proof: Treatment in Lecheng is self-pay. Bank statements or insurance pre-authorization letters are typically required for the visa process.
• Caregiver or family member: Long-protocol treatments benefit from having a caregiver. The zone can help arrange accommodation for accompanying family members.
• Recovery plan: For longer treatments, book post-treatment accommodation in Qionghai or Sanya in advance. Peak season (November to March) fills up quickly.

Estimated Total Cost for International Patients

• BNCT (single-course treatment): $30,000–$60,000 including facility, drug, and physician fees
• CAR-T cell therapy: $80,000–$250,000 depending on product and indication — substantially below US ($1M+) and Singapore ($400,000–$1.5M)
• Targeted oncology drug (course, e.g. ADC): $20,000–$80,000 for a full course depending on drug and indication
• Hospitalization (specialty ward, per week): $3,000–$8,000 for international ward; $1,000–$2,500 for standard Chinese ward
• Flights (round-trip, most origins): $800–$3,000 depending on origin city
• Accommodation (Qionghai or Sanya, 2–6 weeks, mid-range): $1,500–$5,000
• Coordinator, translation, and visa services: $1,000–$3,000
• All-in estimate for a typical Lecheng treatment journey: $40,000–$150,000 for cancer and cell therapy cases — often 40–60% below the cost in Singapore, Japan, or the US for equivalent clinical care

Frequently Asked Questions

Is Boao Lecheng treatment in China safe? What are the risks?

Lecheng facilities operate under Chinese healthcare regulations, with the additional layer of zone-specific rules for cross-border products. The main hospitals in the zone — Ruijin Hainan, Hainan Mellsser, Boao Super Hospital — are joint ventures with established mainland institutions, so clinical standards follow the same protocols as their parent hospitals in Shanghai and Beijing. As with any medical tourism, the specific risks depend on the treatment: BNCT carries standard radiation therapy risks; CAR-T carries cytokine release syndrome and neurotoxicity risks; targeted oncology drugs carry their own side effect profiles. The zone's pre-screening process is designed to confirm that the treatment is appropriate before patients travel.

Can international patients access any drug available abroad in Lecheng?

Not any drug — only the 570 products that have been formally introduced into the zone's special regulatory track. The list is curated and updated by the Hainan provincial government in coordination with NMPA. Common categories include oncology drugs (especially targeted therapies and ADCs), cell and gene therapies, advanced ophthalmology devices, and aesthetic products. To check whether a specific product is on the Lecheng list, contact the zone's medical coordination office through your treatment hospital or through a medical tourism coordinator.

What is boron neutron capture therapy and who is it for?

BNCT is a precision radiation technique that works in two steps. First, the patient is given a boron-containing drug that accumulates preferentially in tumor cells. Then, the tumor is exposed to a beam of low-energy neutrons. The neutrons react with the boron to produce a short-range, high-energy alpha particle that destroys the cancer cell while sparing most of the surrounding healthy tissue. The "kill radius" is about one cell — so damage to healthy tissue is much more limited than with conventional external beam radiation. The most established indications are recurrent head and neck cancers, melanoma, and some high-grade brain tumors. The Hainan BNCT Center is one of the few clinical facilities in East Asia offering BNCT outside of Japan.

How does Lecheng compare to going to Singapore, Thailand, or Japan for medical tourism?

Singapore, Thailand, and Japan are more established medical tourism destinations with longer track records and more developed service cultures. For treatments that are widely available (cardiac surgery, IVF, standard oncology, orthopedics), those destinations remain the default and may offer smoother service. Lecheng's advantage is for treatments that are not yet available in the rest of China — particularly cross-border oncology drugs, BNCT, and CAR-T at lower price points. For Russian, Middle Eastern, and Southeast Asian patients, Hainan is also geographically closer and easier to reach.

Is there a dedicated medical tourism visa for Lecheng?

Not yet. The 86-country visa-free policy covers stays up to 30 days, which is enough for many Lecheng treatments but not for longer protocols. For longer stays, the standard S1 medical visa (3–12 months) is the option, but the application is more involved. Hospital chiefs and medical experts proposed a dedicated medical tourism visa at the 2025 parliamentary session, and the proposal remains under review. Until that changes, most international patients use the visa-free window for short treatments and the S1 visa for longer protocols.

Does insurance cover treatment in Lecheng?

Some international insurers cover treatment at accredited facilities abroad, but Lecheng is not yet on most insurer's approved network lists. The zone is working on international accreditation, but the practical answer for now is that most patients pay out of pocket. Some patients seek reimbursement from their insurers after the fact, with varying success. Confirm coverage with your insurer before assuming any reimbursement.